FMP
Infinity Pharmaceuticals, Inc.
INFI
NASDAQ
Inactive Equity
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
0.008 USD
-0.0088 (-110%)
Latest INFI News
InvestorPlace
Aug 8, 2023
Why Is Infinity Pharmaceuticals (INFI) Stock Up 84% Today?
Infinity Pharmaceuticals (NASDAQ: INFI ) stock is rocketing higher on Tuesday morning despite a lack of news from the biopharmaceutical company. Investors seeking out news concerning shares of INFI stock this morning won't find any new press releases or filings.
Business Wire
Jun 15, 2023
MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncolog...
SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (“MEI”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced today that the companies will host a recorded joint video webcast that will be available at 8:00 am Eastern.
Zacks Investment Research
Mar 28, 2023
Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Lags Revenue Estimates
Infinity (INFI) delivered earnings and revenue surprises of 8.33% and 95.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research
Mar 28, 2023
Will Infinity Pharmaceuticals (INFI) Report Negative Q4 Earnings? What You Should Know
Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Benzinga
Mar 14, 2023
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Cara Therapeutics (NASDAQ:CARA), AdaptHealth (NASDAQ:AHCO)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Zacks Investment Research
Nov 17, 2022
Down 44.4% in 4 Weeks, Here's Why Infinity (INFI) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Infinity (INFI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Seeking Alpha
Nov 14, 2022
Infinity Pharmaceuticals, Inc. (INFI) Q3 2022 Earnings Call Transcript
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Jayne Kauffman - Senior Executive Coordinator Adelene Perkins - Chairman and Chief Executive Officer Robert Ilaria - Chief Medical Officer Larry Bloch - President Conference Call Participants Edward Tenthoff - Piper Sandler Soumit Roy - Jones Research Mayank Mamtani - B. Riley Operator Ladies and gentlemen, thank you for standing by.
Business Wire
Nov 7, 2022
Infinity Pharmaceuticals Announces the Date of Its Third Quarter 2022 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass.
Seeking Alpha
Aug 9, 2022
Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q2 2022 Results - Earnings Call Transcript
Start Time: 16:30 January 1, 0000 4:58 PM ET Infinity Pharmaceuticals, Inc. (NASDAQ:INFI ) Q2 2022 Earnings Conference Call August 09, 2022, 16:30 PM ET Company Participants Adelene Perkins - Chair and CEO Robert Ilaria - CMO Larry Bloch - President Jayne Kauffman - Senior Executive Coordinator Conference Call Participants Edward Tenthoff - Piper Sandler Robyn Karnauskas - Truist Securities Operator Ladies and gentlemen, thank you for standing by. Welcome to the Infinity Pharmaceuticals Conferen...
Business Wire
May 17, 2022
Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the upcoming H.C. Wainwright Global Investment Conference May 23-25, 2022. H.C. Wainwright Global Investment Conference Presentation (hybrid) Date: Tuesday, May 24th
